ArticleNature communications2024
Combined inhibition of KRAS
Abstract read
In one paragraph
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Potential oncogenic role of occult hepatitis B virus pre-S mutations: Activation of Akt/mTOR/Cyclin D1 signaling drives cell cycle dysregulation and proliferation in hepatocellular carcinogenesis.Genes & diseases · 2026Article
- Acquisition of Resistance to RAS Inhibition Is Associated with the Upregulation of Macropinocytosis through Both PI3K-Dependent and -Independent Signaling.Cancer research communications · 2026Article
- Mutant KRAS-driven selective mRNA translation reveals mechanisms and therapeutic vulnerabilities in cancer.Cell reports · 2026Article
- An appendiceal cancer organoid biobank identifies phenotypic evolution and druggable dependencies of peritoneal carcinomatosis.Developmental cell · 2026Article
- Study of the blood-brain barrier-penetrating KRAS G12C inhibitor JMKX1899 in KRAS G12C-mutated NSCLC with brain metastases.Journal of the National Cancer Center · 2026Article
- Autophagy-Apoptosis Crosstalk in Cancer: Mechanisms, Signaling Pathways, and Therapeutic Targeting.Cancers · 2026Review
- Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- The Farnesyl Transferase Inhibitor Darlifarnib (KO-2806) Resensitizes Relapsing Tumors to RAS Inhibition.Cancer research · 2026Article
- Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRASbioRxiv : the preprint server for biology · 2026Article
- AURKA/PHB2 signaling drives acquired resistance to KRASCell death discovery · 2026Article
- Exploring and experimental validation of SLC7A11 and ferroptosis related prognostic genes in non-small cell lung cancer using bulk RNA sequencing and single-cell RNA sequencing.Biology direct · 2026Article
- Systematic and precise interventions for KRAS-mutant cancers.Experimental hematology & oncology · 2026Review
- Farnesyltransferase inhibitor LB42708 disables oncogenic RAS signaling and overcomes gefitinib resistance in NSCLC via FTase α-subunit and RAS degradation.Cell communication and signaling : CCS · 2026Article
- The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Dual inhibition of GTP-bound KRAS and mTOR in lung adenocarcinoma and squamous cell carcinoma harboring KRAS G12C.Cell communication and signaling : CCS · 2025Article
- Review
- Article
- The inhibitory effect of Osthole on A549 lung adenocarcinoma cells and its biomarker.Scientific reports · 2025Article
- eIF4F-mediated dysregulation of mRNA translation in cancer.RNA (New York, N.Y.) · 2025Review
- Molecular principles underlying aggressive cancers.Signal transduction and targeted therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Hidenori Kitai *Program in Molecular Pharmacology and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-6372-846X
Philip H Choi *Program in Molecular Pharmacology and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yu C YangDepartment of Biology, Revolution Medicines Inc., Redwood City, CA, USA.ORCID 0000-0001-8318-1174
Jacob A BoyerProgram in Molecular Pharmacology and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Adele WhaleyProgram in Molecular Pharmacology and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Priya PancholiProgram in Molecular Pharmacology and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0009-0000-9863-130X
Claire ThantProgram in Molecular Pharmacology and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jason ReiterProgram in Molecular Pharmacology and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kevin ChenAntitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Vladimir MarkovAntitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hirokazu TaniguchiDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rui YamaguchiDivision of Cancer Systems Biology, Aichi Cancer Center Research Institute, Nagoya, Aichi, 464-8681, Japan.ORCID 0000-0003-1224-227X
Hiromichi EbiDivision of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya, Aichi, 464-8681, Japan.ORCID 0000-0003-3155-7576
James EvansDepartment of Biology, Revolution Medicines Inc., Redwood City, CA, USA.
Jingjing JiangDepartment of Biology, Revolution Medicines Inc., Redwood City, CA, USA.
Bianca LeeDepartment of Biology, Revolution Medicines Inc., Redwood City, CA, USA.
David WildesDepartment of Biology, Revolution Medicines Inc., Redwood City, CA, USA.ORCID 0009-0009-3855-7270
Elisa de StanchinaAntitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jacqueline A M SmithDepartment of Biology, Revolution Medicines Inc., Redwood City, CA, USA.
Mallika SinghDepartment of Biology, Revolution Medicines Inc., Redwood City, CA, USA. msingh@revmed.com.ORCID 0009-0003-0234-1589
Neal RosenProgram in Molecular Pharmacology and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. rosenn@mskcc.org.ORCID 0000-0002-8307-654X
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MDisparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2MClinical and Translational Science CenterUL1TR000457 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2012 to 2016
$46.0MThe Role of Focal Oncogene Amplifications in Lung CancerP01CA129243 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Marc Ladanyi · 2007 to 2026
$31.2MStudies on oncoprotein-induced feedback: Basic and therapeutic implicationsR35CA210085 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ROSEN, NEAL · 2016 to 2022
$7.3MNCATS NIH HHS UL1 TR000457NCATS NIH HHS UL1 TR002384NCI NIH HHS P01 CA129243NCI NIH HHS P30 CA008748NCI NIH HHS R35 CA210085U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA210085
Abstract
Current KRAS
Indexed as
Carcinoma, Non-Small-Cell LungDrug SynergismLung NeoplasmsMechanistic Target of Rapamycin Complex 1Proto-Oncogene Proteins p21(ras)AnimalsBcl-2-Like Protein 11Cell Line, TumorCyclin D1FemaleHumansMiceMyeloid Cell Leukemia Sequence 1 ProteinProtein Kinase InhibitorsSignal TransductionTOR Serine-Threonine KinasesBcl-2-Like Protein 11Cyclin D1KRAS protein, humanMechanistic Target of Rapamycin Complex 1Myeloid Cell Leukemia Sequence 1 ProteinProtein Kinase InhibitorsProto-Oncogene Proteins p21(ras)TOR Serine-Threonine Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.